Skip to main content
Log in

On the pharmacokinetics and metabolism of propiverine in man

  • Original papers
  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

Summary

The pharmacokinetics ofl4C-propiverine was studied in 13 volunteers and in 2 patients after a single i.v. injection of 5 mg or after oral administration of 15 mg. To each dose 1.11 MBql4C-propiverine was added. The radioactivity measured in plasma, urine (and bile fluid), and the metabolites were estimated by an extraction procedure together with TLC and radiochromatography. Propiverine was eliminated from the plasma with a half-life time ( t05) of 4.1 h (i.v. and per os), while the plasma radioactivity decreased with a t05 of 21.2 (i.v.) or 10.4 h (per os). Within 4 days, 84.5 (i.v.) or 53.5% (per os) of the administered radioactivity was excreted in urine. The absorption of radioactivity of propiverine amounted to 84.5%, while the amount of available propiverine was only 48.9%. In two patients with cannulated ductus choledochus, 21.5 or 14.7% of the administered radioactivity was excreted within 2 days. The metabolic pattern of plasma, urine and bile fluid mainly consisted of amine oxides, substances oxidized in the propyl side chain, desalkylated metabolites, substances with a N-demethylated piperidino group or with ester cleavage, and glucuronide conjugates. Unchanged propiverine appeared in plasma, urine and bile at about 6 to 8% of the administered dose.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Franke G., Zschiesche M., Amon I., (1976): Metabolismus Eiweißbindung von α,α-Diphenyl-n-propylessigsäure-4-(1 -methylpiperidyl)-ester (P4), einem potentiellen Antiparkinsonmittel. 1. Mitt. Kinetik von P 4. Zbl. Pharm.115, 577–592.

    CAS  Google Scholar 

  2. Mohr C, Zschiesche M., Beier R. Hüller H., (1976): Kinetik, Metabolismus und Eiweißbindung von α,α-Diphenyl-n-propoxyessigsäure-4-( 1 -methylpiperidyl)-ester (P 4), einem potentiellen Antiparkinsonmittel. 2. Mitt. Metabolismus und Eiweißbindung von P 4. Zbl. Pharm.115, 593–602.

    CAS  Google Scholar 

  3. Hüller G., Scheithauer S., Haustein, K.-O., (1988): Studies on Metabolism of propiverine (Mictonorm®). Pharmazie43, 91–95.

    PubMed  Google Scholar 

  4. Scheithauer S., (im Druck): Darstellung potentieller Metabolite des Blasenspasmolytikums Propiverin. Pharmazie.

  5. Spittel U., Haustein, K.-O., (1983): FORTRAN-Programm zur Bestimmung von Eliminationsparametern in einem offenen Zwei-Kompartiment-System. Zbl. Pharm.122, 233.

    Google Scholar 

  6. Wagner J.G., (1975): Fundamentals of clinical pharmacokinetics. 1st Ed. Drug Intelligence Publications Inc., Hamilton, Ill.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Haustein, K.O., Hüller, G. On the pharmacokinetics and metabolism of propiverine in man. European Journal of Drug Metabolism and Pharmacokinetics 13, 81–90 (1988). https://doi.org/10.1007/BF03191308

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03191308

Key words

Navigation